Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Dupilumab for Keloids
Recruiting2 awardsPhase 4
New York, New York
This trial is testing a new treatment for keloids (scar tissue) to see if it is better than a placebo. The trial will include 44 people with keloids, and half of them will also have an allergic/inflammatory disease. The treatment will be given weekly for 24 weeks, and then all subjects will receive the treatment for another 28 weeks.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.